Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype

Journal of Infectious Diseases

Volumn 209, Issue 12, 2014, Pages 1941-1948

  Zonios, Dimitrios ^a   Yamazaki, Hiroshi ^b   Murayama, Norie ^b   Natarajan, Ven ^c   Palmore, Tara ^a   Childs, Richard ^d   Skinner, Jeff ^a   Bennett, John E ^a,e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CYP2C19; metabolites; toxicity; voriconazole

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLITE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONFUSION; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HALLUCINATION; HUMAN; INSOMNIA; KERATOACANTHOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN FUNCTION; RASH; RECOMMENDED DRUG DOSE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VISUAL DISORDER;

CYP2C19; METABOLITES; TOXICITY; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALLUCINATIONS; HOMOZYGOTE; HUMANS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 84901806364     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu017     Document Type: Article

References (21)

1. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-11. (Pubitemid 351269158)
2. Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56:4793-9.
3. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011; 12:861-72.
4. Hassan A, Burhenne J, Riedel KD, et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit 2011; 33:86-93.
5. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68:906-15.
6. Blaisdell J, Jorge-Nebert LF, Coulter S, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14:527-37. (Pubitemid 39106854)
7. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methylhydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 2007; 73:2020-6. (Pubitemid 46677908)
8. Perea S, Pennick GJ, Modak A, et al. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother 2000; 44:1209-13. (Pubitemid 30228296)
9. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O. SAS for mixed models. 2nd edn. Cary, NC, USA: SAS Institute Inc, 2006.
10. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649-63. (Pubitemid 43990568)
11. den Hollander JG, van Arkel C, Rijnders BJ, Lugtenburg PJ, de Marie S, Levin MD. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006; 57:1248-50. (Pubitemid 44644436)
12. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003; 56 (Suppl 1): 37-44. (Pubitemid 37491732)
13. Patel AR, Turner ML, Baird K, et al. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2009; 15:370-6.
14. Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29:1240-4.
15. Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis 2008; 47:e7-10.
16. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136:739-42. (Pubitemid 46032197)
17. Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 55:381-90.
18. Wang TF, Wang T, Altman R, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 2009; 9:2845-50.
19. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35:509-13. (Pubitemid 40403355)
20. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 49:196-204.
21. Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009; 65:281-5.